Triple-negative breast cancers

Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1041-1043. doi: 10.1080/14737140.2023.2257393. Epub 2023 Sep 14.

Authors

Steven A Narod^{1

2}, Rebecca Dent³

Affiliations

¹ Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
² Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
³ Department of Medical Oncology, National Cancer Center, Singapore.

PMID: 37707344
DOI: 10.1080/14737140.2023.2257393

No abstract available

Keywords: Triple-negative breast cancer; breast cancer; chemotherapy; pembrolizumab; survival.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Receptor, ErbB-2
Triple Negative Breast Neoplasms* / drug therapy
Triple Negative Breast Neoplasms* / therapy

Substances

Receptor, ErbB-2